T cell lymphomas

Question 1

Primary prognostic feature of ALCL

Answer 1

ALK positivity (positive do very well)

Question 2

PTCL gene expresssion associated with worse OS

Answer 2

GATA3

Question 3

AITL treatment

Answer 3

CHO(E)P + auto-HSCT

Question 4

General management of PTCL

Answer 4

• CHO(E)P (etoposide included)
• consolidate with auto-HSCT in CR1
  *IF CD30+, BV

Question 5

Management of localized nasal NK/T cell lymphoma

Answer 5

SMILE with sandwiched RT
(steroid, MTX, ifos, L-asp, etoposide)

Question 6

Malignancy seen in patient presenting with seroma around breast implant

Answer 6

Breast implant-associated anaplastic large cell lymphoma

Question 7

Management of breast implant-associated anaplastic large cell lymphoma

Answer 7

• remove implant

Question 8

Options for relapsed T-cell lymphoma

Answer 8

• pralatrexate
• HDAC inhibitors
• PI3k inhibitors (duvelisib)

Question 9

pralatrexate mechanism

Answer 9

targeted antifolate

Question 10

romidepsin mechanism

Answer 10

Histone deacetylase (HDAC) inhibitor

Question 11

Sezary syndrome rash presentation

Answer 11

Bright pink erythroderma (looks like a bad diffuse sunburn)

Question 12

First line options for systemic CTCL

Answer 12

Bexarotene (ORR 45%)
Brentuximab

Question 13

clinical features of solitary dermal anaplastic T cell lymphomas

Answer 13

Ulcerated cutaneous mass w/ immunophenotype consistent with t cell lymphoma

Question 14

Initial management of localized solitary dermal anaplastic T cell lymphomas

Answer 14

excision and XRT (indolent disease high with high 5 year survival)

Question 15

Initial management of PTCL, NOS

Answer 15

IF CD30- AND age <60, etoposide + CHOP (no benefit in age >60 due to toxicity)
IF CD30+, BV + chemo (ECHELON-2)

Question 16

AITL immunophenotype

Answer 16

CD4+, CD8-, expanded CD21 follicular dendritic cell network, CD10, PDL1+